

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 3427
HARIHARAN <i>et al.</i>	Art Unit: <i>To Be Assigned</i>
Appl. No.: 10/530,951 (<i>U.S. National Phase of PCT Appl. No. PCT/US03/18253</i>)	Examiner: <i>To Be Assigned</i>
I.A. Filing Date: June 10, 2003	Atty. Docket: 2159.0620008/EKS/J-H
For: Genes Overexpressed By Ovarian Cancer and Their Use In Developing Novel Therapeutics	

Preliminary Amendment Under 37 C.F.R. § 1.115 and Submission of Sequence Listing

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments to the Specification begin on page 2 of this paper

Remarks begin on page 6 of this paper.